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LC-MS/MS PROTEOMIC DETERMINATION OF DUF582 PROTEINS OF 
CHLAMYDIA TRACHOMATIS L2 
Gunna Christiansen1, Lau Sennels2, Allan Stensballe2 and Svend Birkelund2 
1Department of Biomedicine, Aarhus University; 2Department of Health Science and 
Technology, Aalborg University, Denmark 
 
INTRODUCTION 
The coding capacity of the chlamydial genome was revealed by genome sequencing of strain 
D/UW-Cx (Stephens et al. 1998). Of the 894 likely protein-coding genes 255 (28%) were not 
similar to any known proteins indicating the uniqueness of the genus Chlamydia. Since then 
multiple chlamydial and parachlamydial genomes have been sequenced (Stephens et al. 2009) 
but still, many aspects of molecular pathogenesis of chlamydial diseases remain unknown. The 
first attempt to reveal the protein synthesis in chlamydiae was done using two-dimensional 
polyacrylamide gel electrophoresis (2D-PAGE) of in vivo S35 labelled proteins. Hereby we 
showed that among the first proteins to be synthesized were the S1 ribosomal protein, the 
GroEl-like  (HSP60) protein and the DnaK-like protein identified by immunoblotting 
(Lundemose et sl. 1990). Later, when the chlamydial genome became available mass 
spectrometry (MS) was used to identify the protein content within individual protein spots 
separated by 2D-PAGE) (Shaw et al. 2002; Vandahl et al. 2001). With the development of 
more sensitive and sophisticated mass spectrometers in combination with advanced separation 
technology it became possible to make quantitative proteomics (Saka et al. 2011) of purified 
reticulate bodies (RB) and elementary bodies (EB). Using 2D liquid chromatography – tandem 
mass spectrometry (LC/LC-MS/MS) Saka et al. (2011) succeeded in identifying 485 non-
redundant chlamydial proteins (approximately 54% of the predicted proteins in the C. 
trachomatis L2 proteome). When the proteome of purified EB and RB is analyzed, secreted 
proteins may be missed. In the present study we performed LC-MS/MS on complete lysates of 
trypsin digested C. trachomatis L2 infected HeLa cells to determine whether members of the 
Chlamydia-specific, leucine-rich Domain of Unknown Function (DUF)582 protein family could 
be found among the identified proteins. 
 
METHODS 
Cultivation: C. trachomatis L2, strain 434/Bu was cultivated in HeLa cells (ATCC, Rockville, 
MD, USA) with 1 IFU/cell in RPMI medium as described (Hobolt-Pedersen et al. 2009). 
Extraction of proteins: At 43 hpi the C. trachomatis L2 infected monolayers of HeLa cells were 
harvested, washed three times in PBS, and the cells were lyzed in 5% sodium deoxycholate 
(SDC) and 50 mM triethylammonium bicarbonate (TEAB) containing phosphatase inhibitors. 
After heating to 90°C for 5 min. digestion of the samples with trypsin was performed using 
filter aided sample preparation using 10 kDa cutoff spin filters. The resulting protein solution 
was digested with sequencing grade modified trypsin (Promega) at 37°C for 24 hours. After 
trypsin digestion the samples were acidified with trifluoroacetic acid, extracted with ethyl 
acetate, dried down and resuspended in 2% acetonitrile and 1% formic acid. 
Mass spectrometry (MS): MS was done according to Bennike et al. (2013). The protein solution 
was analyzed on an automated LC-ESI MS/MS system using an Ultimate 3000 UPLC system 
with a nanopump module. The system was coupled with an emitter for nanospray ionization to 
a QExactive mass spectrometer (Thermo Scientific, Waltham, USA). Ten  g of the sample was 
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loaded onto the C18 reversed phase column (Dionex) and eluted with a linear gradient of 96% 
solvent A and 4% of solvent B (Bennike et sl. 2013) increasing solvent B to 35% on a 240 min 
ramp gradient. The MS was used in a data dependent mode, selecting the 12 precursor-ions 
with the highest intensity for fragmentation. Resulting raw files were analyzed using Thermo 
Proteome Discoverer, and identified by Mascot (Matrix Science) against a C. trachomatis L2 
Uniprot database. A Homo sapiens database was used to screen the identified chlamydial 
peptides for homology to human proteins. 
Production of polyclonal antibodies: Recombinant CT619 was generated by cloning a PCR 
product encompassing the ct619 gene and expressing the protein and immunization of rabbits 
were done as described by Hobolt-Pedersen et al. (2009). 
Immunofluorescence microscopy: HeLa cells, cultivated on cover slips, were infected with C. 
trachomatis L2 (0.5 IFU/cell) and fixed after 43 hours of infection with 
paraformaldehyde/glutaraldehyde. The infected cells were incubated with the primary antibody 
specific for CT619 followed by incubation with FITC-conjugated goat –anti-rabbit secondary 
antibody (Jackson ImmunoResearch Laboratories, USA). Images were obtained using a Leitz 
DMBRE fluorescence microscope (Leica, Germany) as described (Hobolt-Pedersen et al. 
2009). 
 
RESULTS 
Trypsin digestion will cleave proteins at the peptide bond at the carboxyl side of the amino 
acids lysine (K) and arginine (R) in the primary sequence, thereby cleaving the proteins into 
smaller fragments. The mass of such peptides reflects the amino acid composition of the 
peptide. By MS/MS, fragmentation patterns are generated by collision-induced dissociation 
resulting preferentially in ion dissociation at amide bonds along the peptide backbone, thus 
generating b- and y-type fragment ions (Roepstorff & Fohlman, 1984) and the amino acid 
sequence can be determined. By comparison of the obtained results with in silico generated 
tryptic digests of a translated genome the origin of the peptide is determined. Using the 
translated C. trachomatis L2 genome (Stephens et al. 1998) we searched for peptides belonging 
to the DUF582 protein family (CT619; CT620; CT621; CT711 and CT712 (C. trachomatis D 
genome numbers)). Results are shown in Table 1. Three peptides were identified from CT621, 
a DUF582 protein previous shown to be secreted by the type III secretion system (T3SS) 
(Hobolt-Pedersen et al. 2009; Gong et al. 2011; Muschiol et al. 2011). 
We found no peptides from the DUF582 family members CT620, CT711 and CT712 but from 
CT619 we found four peptides that uniquely identified the protein. None of the identified 
peptides had homology to human proteins. 
The MS/MS spectrum of one of the peptides from CT621 is shown in Fig 1.  It is seen that 
there is a clear y-ion spectrum of peaks indicating the high quality of the amino acid sequence 
of this peptide. 
An even better y-ion spectrum of MS/MS peaks is seen in Fig. 2, clearly demonstrating the 
presence of CT619 in the solution of peptides. 
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Immunofluorescence microscopy of C. trachomatis L2 infected HeLa cells using an antibody 
specific for CT619 is seen in Fig. 3A, and a Nomarsky image of the same cell in Fig. 3B. The 
antibody is seen binding to formed structures within the chlamydial inclusion and only a trace 
of fluorescence is seen in the cytoplasm of the infected cell at 43 hpi, indicating that most of the 
protein is localized within EB/RB at this stage of infection. We therefore cannot determine 
conclusively whether CT619 is secreted. 
 
 
 
DISCUSSION 
LC-MS/MS is a powerful method to identify not only the mass but also the amino acid 
sequence of a peptide. After digestion with trypsin, the complex peptide mixture is separated by 
online LC prior to injection into the MS, for accurate mass measurement. There, selected 
peptides are fragmented in a second MS-event, acquiring accurate fragment masses, thus 
enabling confident identification of the peptide sequence (Figs. 1 and 2). Using whole cell 
extract of C. trachomatis L2 infected HeLa cells, no sample fractionation was performed prior 
to MS-analysis, and therefore no proteins were lost. This is in contrast to gel-based proteomics 
where proteins with extreme pIs frequently are lost, and to proteomics of purified RB and EB 
from which secreted proteins may be lost. 
Table 1.    
Accession number expectancy Peptide sequence 
B0B8J6_CHLT2 
CTL0885/CT621 
9.8e-005 R.SLLSLSNDVMR.V 
5.6e-005 R.TQGSLTDYNSTLEAIAK.K 
 0.00014 R.TQGSLTDYNSTLEAIAK.K 
B0B8J5_CHLT2 
CTL0884/CT620 
  
B0B8J4_CHLT2 
CTL0883/CT619 
7.4e-005 K.ASFNTSTGSTPSLR.A 
7.3e-008 R.IIVEQLAVLDSLLR.S 
 0.012 R.IIVEQLAVLDSLLR.S 
 4e-006 R.IIVEQLAVLDSLLR.S 
B0B8T7_CHLT2 
CTL0080/CT711 
  
B0B8T8_CHLT2CTL008
1/CT712 
  
Fig. 1) CT621/CTL0885  
R.SLLSLSNDVMR.V 
Fig. 2) CT619/CTL0883  
R.IIVEQLAVLDSLLR.S 
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As is the case for CT621, CT619 is a member of the DUF582 family of proteins specific for 
chlamydiae. The size of CT619 is 97 kDa and the protein has a DUF582 domain in its C-
terminal end. This domain is characterized by being leucine-rich but in contrast to CT621, 
CT619 does not contain a leucine zipper, and thus CT619 may serve a function different from 
CT621. In the proteomics study by Saka et al. (2011) CT619 was identified in the EB fraction 
in agreement with the immunofluorescence microscopy image in Fig. 3A. Also CT620 and 
CT711 are expressed at the middle and late phase of the developmental cycle (Muschiol et al. 
2011). The reason why we in the present study did not identify peptides from these proteins 
may be caused by their lower abundance and rapid degradation as demonstrated by Muschiol et 
al. (2011). 
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